Skip to main content

Heroin Dependence

11
Pipeline Programs
4
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
6
0
4
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
3 programs
2
1
Extended-Release NaltrexonePhase 41 trial
Buprenorphine/naloxonePhase 31 trial
Buprenorphine/naloxonePhase 31 trial
Active Trials
NCT00032955Completed163Est. Aug 2002
NCT00032968Completed341Est. Aug 2002
NCT01999946Completed217Est. Dec 2020
Alkermes
AlkermesDUBLIN 4, Ireland
1 program
1
Buprenorphine/naloxonePhase 31 trial
Active Trials
NCT03711318Terminated8Est. Dec 2021
Indivior
IndiviorUK - Slough
1 program
1
Intranasal challenge drugPhase 31 trial
Active Trials
NCT01760473Completed27Est. Dec 2014
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
6 programs
6
Heroin DependencePhase 21 trial
Heroin DependencePhase 21 trial
Opioid-Related DisordersPhase 21 trial
Opioid-Related DisordersPhase 21 trial
Opioid-Related DisordersPhase 21 trial
+1 more programs
Active Trials
NCT00000326Withdrawn0Est. Aug 1997
NCT00000327Withdrawn0Est. Aug 1997
NCT00000328Withdrawn0Est. Aug 1997
+3 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angeles TherapeuticsExtended-Release Naltrexone
AlkermesBuprenorphine/naloxone
IndiviorIntranasal challenge drug
Angeles TherapeuticsBuprenorphine/naloxone
Angeles TherapeuticsBuprenorphine/naloxone
Colorado TherapeuticsTest Drug
Colorado TherapeuticsOpioid-Related Disorders
Colorado TherapeuticsOpioid-Related Disorders
Colorado TherapeuticsOpioid-Related Disorders
Colorado TherapeuticsHeroin Dependence
Colorado TherapeuticsHeroin Dependence

Clinical Trials (11)

Total enrollment: 756 patients across 11 trials

NCT01999946Angeles TherapeuticsExtended-Release Naltrexone

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

Start: Jun 2014Est. completion: Dec 2020217 patients
Phase 4Completed
NCT03711318AlkermesBuprenorphine/naloxone

Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

Start: Nov 2018Est. completion: Dec 20218 patients
Phase 3Terminated
NCT01760473IndiviorIntranasal challenge drug

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

Start: May 2009Est. completion: Dec 201427 patients
Phase 3Completed
NCT00032955Angeles TherapeuticsBuprenorphine/naloxone

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

Start: Feb 2001Est. completion: Aug 2002163 patients
Phase 3Completed
NCT00032968Angeles TherapeuticsBuprenorphine/naloxone

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

Start: Jan 2001Est. completion: Aug 2002341 patients
Phase 3Completed
NCT00000331Colorado TherapeuticsTest Drug

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

Start: Dec 2002Est. completion: Dec 20020
Phase 2Withdrawn
NCT00000330Colorado TherapeuticsOpioid-Related Disorders

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

Start: Oct 1999Est. completion: Nov 19990
Phase 2Withdrawn
NCT00000329Colorado TherapeuticsOpioid-Related Disorders

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

Start: Apr 1999Est. completion: Aug 19990
Phase 2Withdrawn
NCT00000328Colorado TherapeuticsOpioid-Related Disorders

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

Start: Jul 1997Est. completion: Aug 19970
Phase 2Withdrawn
NCT00000327Colorado TherapeuticsHeroin Dependence

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

Start: Jun 1997Est. completion: Aug 19970
Phase 2Withdrawn
NCT00000326Colorado TherapeuticsHeroin Dependence

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1

Start: Apr 1997Est. completion: Aug 19970
Phase 2Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.